European clinical guidelines for Tourette syndrome and other tic disorders: summary statement

  title={European clinical guidelines for Tourette syndrome and other tic disorders: summary statement},
  author={Kirsten R. M{\"u}ller-Vahl and Natalia Szejko and Cara Verdellen and Veit Roessner and Pieter J. Hoekstra and Andreas Hartmann and Danielle C. Cath},
  journal={European Child \& Adolescent Psychiatry},
  pages={377 - 382}
In 2011 a working group of the European Society for the Study of Tourette syndrome (ESSTS) developed the first European Guidelines for Tourette syndrome (TS) published in the ECAP journal. After a decade ESSTS now presents updated guidelines, divided into four sections: Part I: assessment, Part II: psychological interventions, Part III: pharmacological treatment and Part IV: deep brain stimulation (DBS). In this paper, we summarise new developments described in the guidelines with respect to… 
Updated European guidelines for Tourette syndrome: and now use them!
This focused issue of European Child and Adolescent Psychiatry contains fully updated guidelines for the assessment and treatment of Tourette syndrome, written by European experts, and particularly disappointing were insufficient involvement of teachers and schools in the treatment process, limited implementation of psychoeducational methods, as well as a lack of careful examination of patients.
Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.
Increasing evidence suggests that CBM is efficacious in the treatment of tics and psychiatric comorbidities in patients with GTS.
Recent progress on Tourette syndrome
An overview of recent progress on Tourette syndrome is provided, including behavioral therapy, pharmacological treatment, and surgical treatment, for treatment of tics.
Comprehensive behavioural intervention for tics: a neurophysiological intervention
Alongside significant clinical improvements, these results suggest a role for motor cortical Gamma-aminobutyric acid (GABA)-ergic inhibitory circuitry in the neurophysiological changes underlying CBIT treatment.
Treatment failure in persistent tic disorders: an expert clinicians’ consensus-based definition
An expert consensus-based definition of failure of medical treatments for tics, using a multi-step, multi-round, web-based Delphi approach involving international specialist clinicians with specific expertise in tic disorders is achieved.
Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study
MC treatment demonstrates good efficacy and tolerability in adult GTS patients and Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each.
ONLINE-TICS: Internet-Delivered Behavioral Treatment for Patients with Chronic Tic Disorders
Although the primary endpoint was narrowly missed, it is strongly suggested that i CBIT is superior compared to placebo, and treatment effects of iCBIT even increased over time.
Neurology - to be or not to be of the cannabis-based medicine?
  • N. Szejko
  • Medicine, Psychology
    Neurologia i neurochirurgia polska
  • 2022
This edition of the Polish Journal of Neurology and Neurosurgery contains a Leading Topic dedicated to the use of cannabis-based medicine (CBM) in neurology, with four articles that tackle different aspects of CBM use and offer a wide overview, from general information to detailed aspects concerning a particular disease.
The Efficacy of Acupuncture on Tic Disorders in Children: A Retrospective and Propensity Score-Matched Study
Preliminary evidence supporting the therapeutic effect of acupuncture for TD in children indicates that acupuncture could be an adjuvant treatment efficacious forTD in children, especially for vocal tics.
Tourette syndrome: Current nosology and guidelines
  • A. Cavanna
  • Medicine
    International Review of Movement Disorders
  • 2022


European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
A summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice is presented and is not a status quo of a clinically helpful but merely low evidence guideline.
European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation
There is general agreement that, at present time, DBS should only be used in adult, treatment resistant, and severely affected patients and it is highly recommended to perform DBS in the context of controlled trials.
European clinical guidelines for Tourette Syndrome and other tic disorders. Part I: assessment
The first European assessment guidelines of Tourette Syndrome (TS) have been developed and additional specific tools (questionnaires, checklists and neuropsychological tests) are recommended.
European clinical guidelines for Tourette Syndrome and other tic disorders. Part III: behavioural and psychosocial interventions
This clinical guideline provides recommendations for the behavioural and psychosocial interventions (BPI) of children and adolescents with tic disorders prepared by a working group of the European
Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders
Recommendations on the assessment for and use of deep brain stimulation in adults with severe, treatment-refractory tics are provided as well as suggestions for future research.
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders
Evidence to support the efficacy of various medical, behavioral, and neurostimulation interventions for the treatment of tics is demonstrated and harms associated with interventions must be considered in making treatment recommendations.
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry
Deep brain stimulation was associated with symptomatic improvement in patients with Tourette syndrome but also with important adverse events, including intracranial hemorrhage and infection.
A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder.
In comparison with placebo, aripiprazole was efficacious, generally tolerated and safe in the short-term treatment of children and adolescents with Tourette's disorder.
Association of Group A Streptococcus Exposure and Exacerbations of Chronic Tic Disorders
This study does not support GAS exposures as contributing factors for tic exacerbations in children with CTD, and specific workup or active management of GAS infections is unlikely to help modify the course of tics in CTD and is therefore not recommended.